GSE226115 GSE226116 doxorubicin cardiac endothelial cell 2 v 0 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE226115_GSE226116_doxorubicin_cardiac endothelial cell_2_v_0_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE226115_GSE226116_doxorubicin_cardiac endothelial cell_2_v_0_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE226115_GSE226116_doxorubicin_cardiac endothelial cell_2_v_0_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE226115_GSE226116_doxorubicin_cardiac endothelial cell_2_v_0_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

HLA complex P5

Gene

A-kinase anchoring protein 17A

Gene

small nucleolar RNA host gene 1

Gene

mir-100-let-7a-2-mir-125b-1 cluster host gene

Gene

MIR1915 host gene

Gene

long intergenic non-protein coding RNA 3219

Gene

MIR34A host gene

Gene

H3 clustered histone 10

Gene

NIPBL divergent transcript

Gene

long intergenic non-protein coding RNA 2984


  • Gene

    A-kinase anchoring protein 17A


  • Gene

    small nucleolar RNA host gene 1


  • Gene

    mir-100-let-7a-2-mir-125b-1 cluster host gene



  • Gene

    long intergenic non-protein coding RNA 3219



  • Gene

    H3 clustered histone 10


  • Gene

    NIPBL divergent transcript


  • Gene

    long intergenic non-protein coding RNA 2984

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.